Stock Research for ANIK


Featured Broker: Ally Invest

Get the due diligence for another stock.


ANIK Stock Chart & Research Data

The ANIK chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ANIK chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ANIK Due diligence Resources & Stock Charts

The ANIK stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ANIK Detailed Price Forecast - CNN Money CNN View ANIK Detailed Summary - Google Finance
Yahoo View ANIK Detailed Summary - Yahoo! Finance Zacks View ANIK Stock Research & Analysis -

Stock Analysis

TradeIdeas View ANIK Trends & Analysis - Trade-Ideas Barrons View ANIK Major Holders - Barrons
NASDAQ View ANIK Call Transcripts - NASDAQ Seeking View ANIK Breaking News & Analysis - Seeking Alpha
Spotlight View ANIK Annual Report - OTC Report View ANIK OTC Short Report -
TradeKing View ANIK Fundamentals - TradeKing Charts View ANIK SEC Filings - Bar Chart
WSJ View Historical Prices for ANIK - The WSJ Morningstar View Performance/Total Return for ANIK - Morningstar
MarketWatch View the Analyst Estimates for ANIK - MarketWatch CNBC View the Earnings History for ANIK - CNBC
StockMarketWatch View the ANIK Earnings - StockMarketWatch MacroAxis View ANIK Buy or Sell Recommendations - MacroAxis
Bullish View the ANIK Bullish Patterns - American Bulls Short Pains View ANIK Short Pain Metrics -

Social Media Mentions

StockTwits View ANIK Stock Mentions - StockTwits PennyStocks View ANIK Stock Mentions - PennyStockTweets
Twitter View ANIK Stock Mentions - Twitter Invest Hub View ANIK Investment Forum News - Investor Hub
Yahoo View ANIK Stock Mentions - Yahoo! Message Board Seeking Alpha View ANIK Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ANIK - Insider Cow View Insider Transactions for ANIK - Insider Cow
CNBC View ANIK Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ANIK - OTC Markets
Yahoo View Insider Transactions for ANIK - Yahoo! Finance NASDAQ View Institutional Holdings for ANIK - NASDAQ

Stock Charts

FinViz View ANIK Stock Insight & Charts - StockCharts View ANIK Investment Charts -
BarChart View ANIK Stock Overview & Charts - BarChart Trading View View ANIK User Generated Charts - Trading View

Latest Financial News for ANIK

ANIK vs. ALKS: Which Stock Is the Better Value Option?
Posted on Tuesday August 07, 2018

ANIK vs. ALKS: Which Stock Is the Better Value Option?

Analysis: Positioning to Benefit within Anika Therapeutics, Ameris, Century Communities, Energous, Consolidated Communications, and Globalstar — Research Highlights Growth, Revenue, and Consolidated Results
Posted on Tuesday August 07, 2018

NEW YORK, Aug. 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Anika ...

Edited Transcript of ANIK earnings conference call or presentation 26-Jul-18 1:00pm GMT
Posted on Wednesday August 01, 2018

Q2 2018 Anika Therapeutics Inc Earnings Call

Blog Exposure - CHMP Adopts Positive Opinion for Alnylam’s Patisiran for HATTR Amyloidosis Treatment
Posted on Tuesday July 31, 2018

LONDON, UK / ACCESSWIRE / July 31, 2018 / If you want access to our free research report on Alnylam Pharma, Inc. (NASDAQ: ALNY), all you need to do is sign up now by clicking the following link as the Company's latest news hit the wire. On July 27, 2018, the Company announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended a positive opinion recommending marketing authorization of patisiran for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adults with stage 1 or stage 2 polyneuropathy. If approved by the European Commission (EC), the medicine will be commercialized under the brand name ONPATTRO™.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.